‘The bar has risen’: China’s biotech gains push US companies to adapt

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder.

By Ben Fidler • Jan. 17, 2025

Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking

There’s more to pharma's regulatory story in 2025 than just the IRA.

By Meagan Parrish • Jan. 17, 2025

Explore the Trendline➔

Tech for Clinical Trials

Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.

By PharmaVoice staff

By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years

The J.P. Morgan Healthcare Conference has been a focal point for M&A year after year, and after a quiet period, the deals are back on the table.

By Michael Gibney • Jan. 16, 2025

What to expect in the sequel to Medicare’s drug price negotiation program

CMS is expected to publish up to 15 drugs for the second cycle of the program by Feb. 1, and these are some of the drugs most likely to make the list.

By Amy Baxter • Jan. 15, 2025

FTC releases second report slamming pharmacy benefit managers

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.

By Rebecca Pifer • Updated Jan. 14, 2025

Merck is broadening its pipeline as Keytruda’s patent cliff looms

Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.

By Alexandra Pecci • Jan. 14, 2025

Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?

A series of uncertainties that kept dealmaking to a minimum last year could be reversing as pharma reloads pipelines ahead of the patent cliff explosion.

By Michael Gibney • Jan. 14, 2025

The ability to pivot will be ‘key’ as pharma’s tariff threat looms

Companies are looking to new countries like Vietnam for manufacturing needs, but change comes at a cost.

By Kelly Bilodeau • Jan. 13, 2025

FDA ‘stuck to its corner’ with AI draft guidance, leaving plenty of questions unanswered

The first draft guidance provides an initial framework for how the agency will assess AI models in drug development, but the industry is still looking for more.

By Amy Baxter • Jan. 13, 2025

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

Coming changes that could impact pharma from drug development to launch.

By Meagan Parrish • Jan. 10, 2025

3 trial readouts that could shake up the obesity market this year

A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.

By Amy Baxter • Jan. 8, 2025

Subcutaneous options offer convenience for patients — and a valuable window for drugmakers

New formulations for under-the-skin application of drugs give pharmas another opening in a crowded market.

By Kelly Bilodeau • Jan. 7, 2025

PharmaVoice’s Crystal Ball: The industry’s AI future

How AI will further transform the business of drug discovery and development in 2025.

By Meagan Parrish • Jan. 7, 2025

4 closely watched FDA approval dates in 2025 from J&J, Novo and more

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in the new year.

By Alexandra Pecci • Jan. 6, 2025

PBMs have evaded lawmakers’ reform attempts so far. Could 2025 turn the tide?

How regulators could hit PBMs from multiple sides in the coming year.

By Amy Baxter • Jan. 6, 2025

FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end of recent annual tallies.

By Ben Fidler • Jan. 3, 2025

How pharma was instrumental in President Jimmy Carter’s global health efforts

Pharma companies stepped up to support The Carter Center and provide access to life-saving treatments.

By Michael Gibney • Jan. 3, 2025

10 of our most read articles of 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

By Meagan Parrish • Dec. 20, 2024

Zepbound, Mounjaro shortages are resolved, FDA confirms

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.

By Ned Pagliarulo • Dec. 20, 2024

Merck’s RSV antibody could soon paddle into the rough waters of a crowded market

A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.

By Michael Gibney • Dec. 19, 2024

Big Pharma’s new DTC play: partnering with digital health providers

The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.

By Amy Baxter • Dec. 18, 2024

Maternal mortality trends remain dire — and researchers face an uphill battle to solve them

Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.

By Michael Gibney • Dec. 17, 2024

A biotech’s race to tackle the most severe hepatitis

Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.

By Alexandra Pecci • Dec. 17, 2024

3 closely watched drugs that failed in the clinic

How recent setbacks and scattered successes could impact various sectors of the industry.

By Kelly Bilodeau • Dec. 16, 2024

Oncology, obesity and more: Where pharma R&D is headed in 2025

With a little more certainty coming to the market, the R&D environment in 2025 will be about pipeline prioritization and accelerating M&A.  

By Amy Baxter • Dec. 16, 2024